MV130 trains human monocytes in vitro
(A) Schematic representation of the in vitro human monocyte training with MV130.
(B and C) Measurement of both TNFα (B) and IL-6 (C) levels in the supernatants of human monocytes treated as indicated in (A) by ELISA. Each dot represents an independent experiment using monocytes from different donors (n = 6) in independent experiments; mean ± SEM are presented. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 using paired Student's t test.
(D and E) ATAC-seq analysis in human monocytes 5 days after challenge with MV130 or its excipient. Bar plot showing enrichment results for all gene sets in the Hallmark collection. Asterisks denote significant enrichment (FDR q value <0.25). Positive enrichment score (in red) suggests association between gene sets and regions with increased chromatin accessibility in MV130-treated samples. Negative enrichment score is in blue (D). GSEA for inflammatory response and TNFα signaling with their equivalent volcano plots showing biological pathways and genes differentially regulated in excipient- and MV130-treated cells (E).
(F) Oxygen consumption rate (OCR) of human monocytes incubated with excipient or MV130 was analyzed by Seahorse extracellular flux assay at day 5 post challenge. Basal respiration rate (BRR) was defined as OCR before inhibitor addition. Maximal respiration rate (MRR) was defined as the OCR after addition of carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP). Spare respiration capacity (SRC) was defined as the difference between MRR and BRR. Extracellular acidification rate (ECAR) was measured in the absence of inhibitor. Error bars represent SEM. ∗p < 0.05.
(G) Analysis of lactate production in the supernatant of human monocytes 24 h (left, n = 15) and 7 days (right, n = 9) after training with MV130 or excipient. Each dot represents an independent experiment using monocytes from different donors; dots from the same experiment are paired. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 using paired Student's t test.